Status:
TERMINATED
Study of XL999 in Patients With Non-small Cell Lung Cancer
Lead Sponsor:
Symphony Evolution, Inc.
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with non-small cell lung cancer (NSCLC). XL999 is a ...
Eligibility Criteria
Inclusion
- Males and females with histologically confirmed NSCLC
- Prior treatment with a platinum- or taxane containing regimen
- Stage IIIB with malignant effusion, stage IV or recurrent NSCLC that is not amenable to curative therapy (either surgery or radiation therapy)
- Measurable disease according to Response Criteria for Solid Tumors (RECIST)
- ECOG performance status of 0 or 1
- Life expectancy ≥3 months
- Adequate organ and marrow function
- No other malignancies within 5 years
- Signed informed consent
Exclusion
- Radiation to ≥25% of bone marrow within 30 days of XL999 treatment
- Use of any systemic anticancer therapy within 30 days of XL999 treatment
- More than 2 prior systemic cytotoxic chemotherapy regimens
- More than 1 prior agent targeted against VEGF or EGFR (eg, bevacizumab, erlotinib, or gefitinib)
- Subject has not recovered to ≤ grade 1 or to within 10% of baseline from adverse events due to other medications administered \>30 days before study enrollment
- Uncontrolled and/or intercurrent illness
- History of or known brain metastases, current spinal cord compression, or carcinomatous meningitis
- Pregnant or breastfeeding females
- Known HIV
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00277329
Start Date
December 1 2005
End Date
July 1 2008
Last Update
February 22 2010
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Hematology/Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida, United States, 34952
2
Joliet Oncology-Hematology Associates, Ltd.
Joliet, Illinois, United States, 60435
3
Hematology-Oncology Associates of Rockland
Nyack, New York, United States, 10960
4
Center for Oncology Research and Treatment, PA
Dallas, Texas, United States, 75230